Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics
| Autor: | M. Trang, E. A. Lakota, M. C. Safir, S. M. Bhavnani, L. Friedrich, J. N. Steenbergen, P. C. McGovern, E. Tzanis, C. M. Rubino |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Antimicrobial Agents and Chemotherapy. 67 |
| ISSN: | 1098-6596 0066-4804 |
| DOI: | 10.1128/aac.02397-21 |
| Popis: | Omadacycline is approved in the United States for the treatment of patients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections. Analyses were undertaken to evaluate pharmacokinetic differences among subjects or patients stratified by comorbidities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|